The announcement comes weeks after President Donald Trump inked deals with Eli Lilly and Novo Nordisk to make their GLP-1 drugs easier for Americans to access.
In this article
Eli Lilly
on Monday said it is lowering the cash prices of single-dose vials of its blockbuster weight loss drug Zepbound on its direct-to-consumer platform, LillyDirect, building on efforts by the company and the Trump administration to make the medicine more accessible.
The announcement also comes weeks after chief rival Novo Nordisk
unveiled additional discounts on the cash prices of its obesity and diabetes drugs.
Lilly's Zepbound price cuts ranged from $50 to $100, depending on the dosage, for consumers who pay cash via the drugmaker's…
The pharmaceutical giant and Novo Nordisk said they would lower the prices of their popular weight loss drugs to expand access.
Starting in mid-November, cash-paying patients can purchase Zepbound vials at discounts of 50% or more through the retailer's…
The deal, which includes Eli Lilly and Novo Nordisk, will slash prices for Medicare and Medicaid programme recipients.
Eli Lilly hopes the device can be more convenient for Zepbound users and lead to more people taking the drug.
Eli Lilly and Novo Nordisk officials have agreed to lower the cost of GLP-1 obesity drugs for Medicaid and Medicare recipients…
